Careers Contact Us
Facebook Twitter LinkedIn
logo_abeona_retina
  • Home
  • About
    • Mission
    • Leaders
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
    • Recessive Dystrophic Epidermolysis Bullosa (RDEB)
  • Patients & Families
    • Patient Advocacy & Community Engagement (PACE)
    • Our Focus
    • Resources
    • Our Inspiration
    • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us
×
  • Home
  • About
    • Mission
    • Leaders
  • Science
    • Pipeline
    • Manufacturing
    • The AIMTM Vector
  • Clinical Trials
    • Overview
    • Recessive Dystrophic Epidermolysis Bullosa (RDEB)
  • Patients & Families
    • Patient Advocacy & Community Engagement (PACE)
    • Our Focus
    • Resources
    • Our Inspiration
    • Access Policy
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Press Releases

Investors

Investors & Media

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Events
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Scientific Advisory Board
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Events
  • Email Alerts

Abeona Therapeutics Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL™ Study Results for Oral Presentation at International Societies for Investigative Dermatology (ISID) 2023 Meeting

Mar 16, 2023

Abeona Therapeutics Announces Update on AAV Ophthalmology Program

Mar 14, 2023

Abeona Therapeutics Reports Third Quarter 2022 Financial Results

Nov 14, 2022

Abeona Therapeutics Announces $35 Million Private Placement Financing

Nov 3, 2022

Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101

Nov 3, 2022

Abeona Therapeutics Announces Database Lock for Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Oct 19, 2022

Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Oct 4, 2022

Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit

Sep 22, 2022

Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference

Sep 13, 2022

Abeona Therapeutics Reports Second Quarter 2022 Financial Results

Aug 11, 2022
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...25

© 2023 Abeona Therapeutics Inc. All Rights Reserved. | Privacy Policy